|
|
| | CP 544326 Basic information |
| Product Name: | CP 544326 | | Synonyms: | CP 544326;PF 04217329;CP544326 (Taprenepag);2-[3-[[[[4-(1H-Pyrazol-1-yl)phenyl]methyl](3-pyridinylsulfonyl)amino]methyl]phenoxy]acetic acid;Taprenepag(CP-544326);CP-544326;CP544326;CP 544326;2-[3-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]phenoxy]acetic Acid;Acetic acid, 2-[3-[[[[4-(1H-pyrazol-1-yl)phenyl]methyl](3-pyridinylsulfonyl)amino]methyl]phenoxy]- | | CAS: | 752187-80-7 | | MF: | C24H22N4O5S | | MW: | 478.52 | | EINECS: | | | Product Categories: | | | Mol File: | 752187-80-7.mol |  |
| | CP 544326 Chemical Properties |
| Boiling point | 716.8±70.0 °C(Predicted) | | density | 1.34±0.1 g/cm3(Predicted) | | storage temp. | Sealed in dry,Room Temperature | | solubility | DMF: 20 mg/ml; DMSO: 30 mg/ml; Ethanol: slightly soluble | | form | A crystalline solid | | pka | 3.14±0.10(Predicted) | | color | White to off-white |
| | CP 544326 Usage And Synthesis |
| Uses | Taprenepag is a selective EP2 receptor agonist administered as a topical ophthalmic solution against ocular hypertension. |
| | CP 544326 Preparation Products And Raw materials |
|